Neoantigen-specific Adoptive T cell Therapies in Cancer

To develop manufacturing procedures for large scale production of neoantigen-specific CD8+ T cells for clinical applications.

Goals:

• To develop manufacturing procedure for large scale production of neoantigen-specific CD8+ T cells for clinical application
• Perform a pilot (proof-of-concept) clinical trials using expanded neoantigen-specific T cells to treat relapsed/refractory metastatic melanoma and other cancers

Accomplishments:

• We have procure a GMP-grade leukemia (K562) cell line transduce with HLA-A*02:01 and CD137L (refer to as 2D11) from CVPF for T cell expansion
• Successful cloning of TCRs specific for six unique melanoma neoantigens that were identified in our previous publications.
• Our current efforts are focused on the identification of novel TCRs specific for novel gp100/PMel17 peptides.

Project Participants:  Gerald Linette, Beatriz Carreno, Lorea Baroja, Casey Cummings and Andrea Brennan